Sequenom Q2 Revenues Rise Sharply, but Miss Analyst Estimates; Lashes Out at MDx Code Changes | GenomeWeb

NEW YORK (GenomeWeb News) – Sequenom reported after the close of the market on Wednesday that its revenues in the second quarter jumped 91 percent year over year, but missed the consensus Wall Street estimate as changes in molecular diagnostic billing and payment codes delayed receipt of payments.

For the three months ended June 30, the San Diego-based company pulled in $34.9 million in total revenues, compared to $18.3 million a year ago, but was well short of the consensus analyst estimate of $46.3 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: researchers explore the transfer of host genetic material into viruses, and more.

It's too difficult to correct or retract a flawed scientific paper, researchers write in Nature.

A proposed bill would require NSF to only fund research that's in "the national interest."

Australia's Commonwealth Scientific and Industrial Research Organisation plans to eliminate up to 350 jobs.

Feb
25
Sponsored by
Omicia

This webinar will demonstrate how ACMG's recommended variant scoring and classification rules may be applied to standardize reporting on sequencing test results within and across institutions. 

Mar
03
Sponsored by
Agilent Technologies

This webinar will discuss the use of a hybrid capture-based FFPE DNA sequencing methodology with the potential for advancing precision oncology studies. 

Mar
17
Sponsored by
Qiagen

This webinar will discuss Qiagen's approach to address two challenges facing NGS in the clinical research setting: lack of seamless workflow for routine clinical research use and truly relevant content to guide clinical research activities.